Navigation Links
SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease
Date:9/1/2008

Center for Congenital & Structural Heart Disease, Section Chief of Pediatric Cardiology, and Professor of Pediatrics & Internal Medicine at Rush University Medical Center (Chicago, IL).

"The take-away message is that SYNTAX has extended the spectrum of care for a large number of patients with very complex coronary artery disease. For some, bypass surgery will still be the most appropriate option, but many more patients now have another choice," says Dr. Feldman.

About SCAI

Headquartered in Washington, D.C., The Society for Cardiovascular Angiography and Interventions is a 4,000-member professional organization representing invasive and interventional cardiologists in more than 60 countries. SCAI's mission is to promote excellence in invasive and interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI's annual meeting has become the leading venue for education, discussion, and debate about the latest developments in this dynamic medical specialty. SCAI's new patient and physician education program, Seconds Count, offers comprehensive information about cardiovascular disease. For more information about SCAI and Seconds Count, visit http://www.scai.org or http://www.seconds-count.org.


'/>"/>
SOURCE Society for Cardiovascular Angiography and Interventions(SCAI)
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI
2. New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option
3. ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer
4. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
5. Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 3454
6. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
7. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
8. GSK Does Not Option XL784 for Further Development
9. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
10. Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel
11. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2Study to Investigate AHCC and the Swine Flu Virus 47555 1Study to Investigate AHCC and the Swine Flu Virus 47555 2Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 1Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 2Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 3Consumer Reports 3A Hearing Aid Shoppers Pay High Prices Get Mediocre Fittings 47551 4PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 1PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 2PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 3PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 4PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 5PROTECT 1 Phase II III Induction Stage Results for ChemoCentryxs Traficet EN 28TM 29 Presented in Oral Session at DDW 2009 Conference 4508 6
Breaking Medicine News(10 mins):Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:U.S. Cancer Cases, Deaths Continue to Drop 2Health News:U.S. Cancer Cases, Deaths Continue to Drop 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 4Health News:New approach to sickle-cell disease shows promise in mice 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5